Program
ocrelizumab
Also written as “Ocrelizumab”, “CYB704” and “OCR SC”.
Its studies are mostly in Multiple Sclerosis · Arthritis, Rheumatoid · Multiple Sclerosis, Chronic Progressive · Multiple Sclerosis, Relapsing-Remitting · Lupus Nephritis, led by 5 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Hoffmann-La Roche | 3810 open or running | phase 4since Jul 5, 2018 | Feb 12, 2004 | Dec 31, 2027phase 3 · NCT05269004 |
| Celltrion | 11 open or running | phase 3since May 9, 2023 | May 9, 2023 | Feb 2027phase 3 · NCT05906992 |
| Cinnagen | 10 open or running | phase 3since Jun 27, 2021 | Jun 27, 2021 | none ahead |
| R-Pharm | 11 open or running | phase 1since Apr 13, 2026 | Apr 13, 2026 | none ahead |
| Sandoz | 11 open or running | phase 3since Feb 19, 2025 | Feb 19, 2025 | none ahead |
Also a collaborator on its studies: ppd-development-lp, laboratory-corporation-of-america and roche-pharma-ag.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 26 studies since Feb 12, 2004.
- May 1, 2020Phase 4 study in Multiple SclerosisHoffmann-La Roche · NCT04377555 · 179 enrolled · United States, Kenya, Puerto Rico
- Sep 4, 20202 phase 3 studies in Multiple SclerosisHoffmann-La Roche · NCT04544436, NCT04548999
- Jun 27, 2021Cinnagen's first study: phase 3 study in Multiple SclerosisNew to CinnagenCinnagen · NCT04966338 · 170 enrolled · Iran, Islamic Republic of
- Aug 6, 20212 phase 4 studies in Multiple SclerosisHoffmann-La Roche · NCT04998851, NCT04998812
- Nov 16, 2021Phase 3 study in Multiple Sclerosis, Relapsing-RemittingHoffmann-La Roche · NCT05123703 · 188 enrolled · United States, Argentina, Australia and more
- Jan 12, 2022Phase 4 study in Multiple SclerosisHoffmann-La Roche · NCT05208840 · Russian Federation
- Jan 27, 2022Phase 3 study in Multiple Sclerosis, Chronic ProgressiveHoffmann-La Roche · NCT05232825 · 236 enrolled · United States, Brazil, Czechia and more
- Feb 11, 2022Phase 3 study in Multiple SclerosisHoffmann-La Roche · NCT05269004 · 1,300 enrolled · United States, Argentina, Australia and more
- May 9, 2023Celltrion's first study: phase 3 study in Multiple Sclerosis, Relapsing-RemittingNew to CelltrionCelltrion · NCT05906992 · 512 planned · Poland
- Nov 4, 2024Phase 3 study in Multiple SclerosisHoffmann-La Roche · NCT06675955 · 500 planned · Bulgaria, France, Germany and more
- Feb 19, 2025Sandoz's first study: phase 3 study in Relapsing Multiple SclerosisNew to SandozSandoz · NCT06847724 · 183 enrolled · United States, Bosnia and Herzegovina, Bulgaria and more
- Mar 16, 2026Phase 4 study in Multiple Sclerosis, Chronic ProgressiveHoffmann-La Roche · NCT07483450 · 60 enrolled · China
- Apr 13, 2026R-Pharm's first study: phase 1 study in Multiple SclerosisNew to R-PharmR-Pharm · NCT07597668 · 180 enrolled · Russia
- May 20, 2026Phase 4 study in Multiple SclerosisHoffmann-La Roche · NCT07609719 · 100 planned · United States, Puerto Rico
Ahead
- Nov 3, 2026Primary completion: phase 3 study in Relapsing Multiple SclerosisSandoz · NCT06847724
- Feb 2027Primary completion: phase 3 study in Multiple Sclerosis, Relapsing-RemittingCelltrion · NCT05906992
- Dec 31, 2027Primary completion: phase 4 study in Multiple Sclerosis, Chronic ProgressiveHoffmann-La Roche · NCT07483450
- Dec 31, 2027Primary completion: phase 3 study in Multiple SclerosisHoffmann-La Roche · NCT05269004
TargetBeta
“A Fc-modified, humanized monoclonal antibody directed against the B-cell CD20 cell surface antigen, with immunosuppressive activity”NCIt, by rule
“B-lymphocyte antigen CD20 binding agent”ChEMBL 37, by rule
Other programs on MS4A1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Rituximabrule | Hoffmann-La Roche | phase 4 | 175 |
| obinutuzumabrule | Hoffmann-La Roche | phase 4 | 42 |
| ublituximabrule | TG Therapeutics | phase 3 | 23 |
| mosunetuzumabrule | Hoffmann-La Roche | phase 3 | 14 |
| glofitamabrule | Hoffmann-La Roche | phase 3 | 13 |
| epcoritamabrule | Genmab | phase 3 | 13 |
| Anti-CD20 Monoclonal Antibody MIL62rule | beijing-mabworks-biotech-co-ltd | phase 3 | 10 |
| odronextamabrule | Regeneron Pharmaceuticals | phase 3 | 8 |
| TQB2825 | Sino Biopharmaceutical | phase 3 | 5 |
| zuberitamabrule | bioray-pharmaceutical-co-ltd | phase 3 | 3 |
| rondecabtagene autoleucelrule | lyell-immunopharma-inc | phase 3 | 2 |
| zamtocabtagene autoleucelrule | miltenyi-biomedicine-gmbh | phase 2 | 8 |
Studies
All 42 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07609719Multiple Sclerosis · United States, Puerto Rico | 4 | Recruiting | Hoffmann-La Roche | Feb 28, 2029 | 100 |
| NCT07597668Multiple Sclerosis · Russia | 1 | Active, not recruiting | R-Pharm | Jun 2, 2026 | 180 |
| NCT07483450Multiple Sclerosis, Chronic Progressive · China | 4 | Active, not recruiting | Hoffmann-La Roche | Dec 31, 2027 | 60 |
| NCT06847724Relapsing Multiple Sclerosis · United States, Bosnia and Herzegovina, Bulgaria and more | 3 | Active, not recruiting | Sandoz | Nov 3, 2026 | 183 |
| NCT06675955Multiple Sclerosis · Bulgaria, France, Germany and more | 3 | Recruiting | Hoffmann-La Roche | Dec 31, 2029 | 500 |
| NCT05906992Multiple Sclerosis, Relapsing-Remitting · Poland | 3 | Recruiting | Celltrion | Feb 2027 | 512 |
| NCT05269004Multiple Sclerosis · United States, Argentina, Australia and more | 3 | Active, not recruiting | Hoffmann-La Roche | Dec 31, 2027 | 1,300 |
| NCT05232825Multiple Sclerosis, Chronic Progressive · United States, Brazil, Czechia and more | 3 | Completed | Hoffmann-La Roche | Mar 10, 2023 | 236 |
| NCT05208840Multiple Sclerosis · Russian Federation | 4 | Withdrawn | Hoffmann-La Roche | Jan 31, 2025 | 0 |
| NCT05123703Multiple Sclerosis, Relapsing-Remitting · United States, Argentina, Australia and more | 3 | Active, not recruiting | Hoffmann-La Roche | Jun 9, 2025 | 188 |
| NCT04998851Multiple Sclerosis · United States, Spain, United Kingdom | 4 | Completed | Hoffmann-La Roche | Mar 29, 2024 | 26 |
| NCT04998812Multiple Sclerosis · United States, France, Germany and more | 4 | Completed | Hoffmann-La Roche | Apr 8, 2024 | 70 |
| NCT04966338Multiple Sclerosis · Iran, Islamic Republic of | 3 | Completed | Cinnagen | Nov 9, 2020 | 170 |
| NCT04548999Multiple Sclerosis · United States, Argentina, Belgium and more | 3 | Active, not recruiting | Hoffmann-La Roche | Jun 30, 2025 | 769 |
| NCT04544436Multiple Sclerosis · United States, Argentina, Australia and more | 3 | Active, not recruiting | Hoffmann-La Roche | Dec 19, 2024 | 864 |
| NCT04377555Multiple Sclerosis · United States, Kenya, Puerto Rico | 4 | Completed | Hoffmann-La Roche | Dec 15, 2022 | 179 |
| NCT04075266Multiple Sclerosis · United States, Italy, Poland | 2 | Active, not recruiting | Hoffmann-La Roche | Oct 5, 2023 | 23 |
| NCT04035005Multiple Sclerosis, Chronic Progressive · United States, Australia, Belgium and more | 3 | Active, not recruiting | Hoffmann-La Roche | Jan 15, 2025 | 1,013 |
| NCT03972306Multiple Sclerosis · United States | 1 | Completed | Hoffmann-La Roche | Jun 3, 2025 | 134 |
| NCT03606460Multiple Sclerosis · United States | 3 | Completed | Hoffmann-La Roche | May 31, 2019 | 141 |
| NCT03589105Multiple Sclerosis · France | 4 | Completed | Hoffmann-La Roche | Feb 15, 2021 | 423 |
| NCT03599245Multiple Sclerosis · Argentina, Belgium, Brazil and more | 3 | Completed | Hoffmann-La Roche | Jul 17, 2025 | 1,055 |
| NCT03523858Multiple Sclerosis, Chronic Progressive · United States, Bosnia and Herzegovina, Brazil and more | 3 | Active, not recruiting | Hoffmann-La Roche | Oct 22, 2026 | 927 |
| NCT03085810Multiple Sclerosis, Relapsing-Remitting · United States, Argentina, Australia and more | 3 | Terminated | Hoffmann-La Roche | Apr 27, 2023 | 1,225 |
| NCT02861014Multiple Sclerosis, Relapsing-Remitting · Australia, Belgium, Czechia and more | 3 | Completed | Hoffmann-La Roche | Oct 25, 2019 | 681 |
| NCT02723071Lymphoma, Non-Hodgkin · Australia, Canada, France and more | 2 | Completed | Hoffmann-La Roche | Jan 2008 | 48 |
| NCT02720120Arthritis, Rheumatoid · Australia, Belgium, Canada and more | 2 | Terminated | Hoffmann-La Roche | Feb 2013 | 175 |
| NCT02688985Multiple Sclerosis, Chronic Progressive · United States, Canada, Germany and more | 3 | Completed | Hoffmann-La Roche | Apr 11, 2023 | 131 |
| NCT02637856Multiple Sclerosis, Relapsing-Remitting · United States, Canada | 3 | Completed | Hoffmann-La Roche | May 3, 2019 | 608 |
| NCT01412333Relapsing Multiple Sclerosis · United States, Argentina, Belarus and more | 3 | Completed | Hoffmann-La Roche | May 12, 2015 | 835 |
| NCT01247324Relapsing Multiple Sclerosis · United States, Argentina, Australia and more | 3 | Completed | Hoffmann-La Roche | Apr 2, 2015 | 821 |
| NCT01194570Multiple Sclerosis, Chronic Progressive · United States, Australia, Austria and more | 3 | Completed | Hoffmann-La Roche | Jul 23, 2015 | 735 |
| NCT00808210Arthritis, Rheumatoid · United States | 2 | Terminated | Hoffmann-La Roche | Nov 14, 2012 | 28 |
| NCT00779220Arthritis, Rheumatoid · Japan | 2 | Terminated | Hoffmann-La Roche | Feb 2010 | 152 |
| NCT00676715Multiple Sclerosis, Relapsing-Remitting · United States, Belgium, Bulgaria and more | 2 | Completed | Hoffmann-La Roche | Mar 9, 2012 | 220 |
| NCT00673920Arthritis, Rheumatoid | 3 | Terminated | Hoffmann-La Roche | Oct 26, 2009 | 314 |
| NCT00626197Lupus Nephritis | 3 | Terminated | Hoffmann-La Roche | Oct 19, 2009 | 381 |
| NCT00539838Lupus Erythematosus, Systemic | 3 | Terminated | Hoffmann-La Roche | Jul 12, 2011 | 33 |
| NCT00485589Arthritis, Rheumatoid | 3 | Terminated | Hoffmann-La Roche | Jan 29, 2010 | 613 |
| NCT00476996Arthritis, Rheumatoid · United States, Argentina, Australia and more | 3 | Terminated | Hoffmann-La Roche | Jan 21, 2010 | 836 |
| NCT00406419Arthritis, Rheumatoid · United States | 3 | Terminated | Hoffmann-La Roche | Oct 6, 2009 | 1,015 |
| NCT00077870Arthritis, Rheumatoid | 2 | Completed | Hoffmann-La Roche | 237 |
How it is read
Names in the registry
- “Ocrelizumab”, 36 entries
- “ocrelizumab”, 2 entries
- “CYB704”, 1 entry
- “OCR SC”, 1 entry
- “Ocrelizumab SC”, 1 entry
Conditions, from the studies’ own filings
- Multiple Sclerosis, 18 studies
- Arthritis, Rheumatoid, 8 studies
- Multiple Sclerosis, Chronic Progressive, 7 studies
- Multiple Sclerosis, Relapsing-Remitting, 6 studies
- Lupus Nephritis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.